This review summarizes current knowledge on pituitary changes in patients with acromegaly. The histologic, immunohistochemical and electron microscopic study provided conclusive evidence that a marked diversity exists between the tumors which secrete growth hormone (GH) in excess, such as densely and sparsely granulated GH cell adenoma, the mixed GH prolactin cell adenoma and the mammosomatotrope adenoma. The latter two tumors produce GH and prolactin simultaneously. Densely granulated GH cell tumors may produce thyrotropin and α subunit as well. Somatotrope carcinomas are extremely rare. GH cell hyperplasia can also be associated with acromegaly in patients with extrapituitary GH-releasing hormone secreting tumors. The medical therapy of acromegaly is reviewed briefly, including long-acting somatostatin analogs and pegvisomant, a GH receptor blocker.

Keywords:
Acromegaly, Growth hormone, Pituitary neoplasm
1.
Kovacs K, Scheithauer BW, Horvath E, Lloyd RV: The World Health Organization classification of adenohypophysial neoplasms: a five-tier scheme. Cancer 1996;78:502–510.
2.
Kovacs K, Horvath E: Tumors of the pituitary gland; in Hartmann WH, Sobin LH (eds): Atlas of Tumor Pathology, 2nd series, fascicle 21. Washington, Armed Forces Institute of Pathology, 1986.
3.
Kovacs K, Horvath E: Pathology of growth hormone producing tumors of the human pituitary. Semin Diagn Pathol 1986;3:18–33.
4.
Horvath E, Scheithauer BW, Kovacs K: Morphological aspects of growth hormone producing pituitary adenomas with emphasis on novel concepts; in Lüdecke DK, Tolis G (eds): Growth Hormone, Growth Factors and Acromegaly. New York, Raven Press, 1987, pp 107–114.
5.
Horvath E, Kovacs K: The adenohypophysis; in Kovacs K, Asa SL (eds): Functional Endocrine Pathology, ed 2. Malden, Blackwell, 1998, pp 247–281.
6.
Horvath E, Scheithauer BW, Kovacs K, Lloyd RV: Hypothalamus and pituitary; in Graham DI, Lantos PL (eds): Greenfield’s Neuropathology, ed 7. London, Arnold, 2002, pp 983–1062.
7.
Scheithauer BW, Kovacs K, Horvath E, Roncaroli F, Ezzat S, Asa SL, Nosé V, Watson RE Jr, Lindell EP: Pituitary carcinoma; in DeLellis RA, Lloyd RV, Heitz PN, Eng C (eds): World Health Organization Classification of Tumors. Pathology and Genetics, Tumors of Endocrine Organs. Lyon, IARC Press, 2004, pp 36–47.
8.
Thorner MO, Perryman RL, Cronin MJ, Draznin MB, Johanson AJ, Rogol AD, Jane JA, Rudolf LE, Horvath E, Kovacs K, Vale W: Somatotroph hyperplasia: successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone releasing factor. Trans Assoc Am Physicians 1982;95:177–178.
9.
Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K: Ghrelin is a growth hormone releasing acylated peptide from stomach. Nature 1999;402:656–660.
10.
Corbetta S, Peracchi M, Cappiello V, Lania E, Vago L, Beck-Peccoz P, Spada A: Circulating ghrelin levels in patients with pancreatic and gastrointestinal neuroendocrine tumors: identification of one pancreatic ghrelinoma. J Clin Endocrinol Metab 2003;88:3117–3120.
11.
Thorner MO, Martin WH, Rogol AD, Morris JL, Perryman RL, Conway BP, Howards SS, Wolfman HG, MacLeod RM: Rapid regression of pituitary prolactinomas during bromocriptine treatment. J Clin Endocrinol Metab 1980;51:438–445.
12.
Tindall GT, Kovacs K, Horvath E, Thorner MO: Human prolactin producing adenomas and bromocriptine: a histological, immunocytochemical, ultrastructural and morphometric study. J Clin Endocrinol Metab 1982;55:1178–1183.
13.
Jaffe CA, Barkan AL: Treatment of acromegaly with dopamine agonist. Endocrinol Metab Clin North Am 1992;21:713–735.
14.
Harris AG, Prestele H, Herold K, Boerlin V: Long term efficacy of Sandostatin (SMS 201-995, Octreotide) in 178 acromegalic patients. Results from the International Multicentre Acromegaly Study Group; in Lamberts SWJ (ed): Sandostatin in the Treatment of Acromegaly. Berlin, Springer, 1988, pp 117–125.
15.
Freda PU: Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2002;87:3013–3018.
16.
Vance ML: Medical treatment of functional pituitary tumors. Neurosurg Clin North Am 2003;14:81–89.
17.
Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ: Growth hormone receptor antagonists: discovery, development and use in patients with acromegaly. Endocr Rev 2002;23:623–646.
18.
Parkinson C, Trainer DJ: The place of pegvisomant in the management of acromegaly. Endocrinologist 2003;13:408–416.
19.
Paisley AN, Drake WH: Treatment of pituitary tumors. Pegvisomant. Endocrine 2005;28:111–114.
20.
Newlands ES, Stevens MFG, Wedge SR, Wheelhouse RT, Brock C: Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997;23:35–61.
21.
Fadul CE, Kominsky AL, Meyer LP, Kingman LS, Kinlaw WB, Rhodes CH, Eskey CJ, Pepin SE, Simmons NE: Pituitary carcinomas respond to Temozolomide. Neurooncology 2004;6:374.
22.
Zhu Y, Shahinian H, Hakimian B, Bonert V, Lim S, Heaney A: Temodar: novel treatment for pituitary carcinoma (abstract). US Endocr Soc 2004;43:138.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.